Showing results (721-730 of 792) with videos related to

Sort By:
Pageof 80
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Blood|March 10, 2009
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host diseasePaul J Martin, Barry E Storer, Scott D Rowley, et al.
Leukemia & Lymphoma|February 17, 2015
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemiaJonathan How, Mark D Minden, Leber Brian, et al.
Blood|January 2, 2026
A Stem and Progenitor Cell-Derived Gene Expression Signature is Prognostic for Survival in MyelofibrosisJessie J F Medeiros, Andy G X Zeng, Suraj Bansal, et al.
Blood Advances|October 18, 2018
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomesCaroline J McNamara, Tony Panzarella, James A Kennedy, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.
Haematologica|July 6, 2023
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaborationTania Jain, Hua-Ling Tsai, Hany Elmariah, et al.
American Journal of Hematology|November 26, 2013
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignanciesMark D Minden, Donna E Hogge, Scott J Weir, et al.
Pageof 80